Pirlindole in the treatment of depression: A meta-analysis

Clinical Drug Investigation

Volumn 31, Issue 1, 2011, Pages 61-71

  MacEdo, Ana ^a   Leiria, Eva ^a   Filipe, Augusto ^b  

^a Consultoria Cientfica Lda ^*  (Portugal)

^b Tecnimede Group   (Portugal)

Author keywords

Antidepressants, therapeutic use; Depression, treatment; Pirlindole, therapeutic use

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; PIRLINDOLE; PLACEBO;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SLEEP DISORDER; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CARBAZOLES; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78149376625     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586690-000000000-00000     Document Type: Article

References (29)

1. WHO. Mental health [online]. Available from URL: http://www.who.int/ mental-health/management/depression/definition/en/ [Accessed 2010 May 17]
2. EatonW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008; 65: 513-20
3. Bschor T, Adli M. Continuing medical education: treatment of depressive disorders. Dtsch Arztebl Int 2008; 105: 782-92
4. Möller H-J, Volz HP. Drug treatment of depression in the1990s: an overview of achievements and future possibilities. Drugs 1996; 52: 625-38
5. Mö ller H-J, Mü ller WE, Volz HP. Psychopharmakotherapie: ein Leitfaden fü r Klinik und Praxis. 2nd ed. Stuttgart Berlin Kö ln: Kohlhammer, 2000
6. Patkar AA, Pae C, Masand P. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006; 5: 363-75
7. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and broforamine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226-47
8. Fowler JS, Logan J, Azzaro AJ, et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 2010; 35: 623-31
9. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008; 60: 1527-33
10. Johnston JP. Some observations upon a new inhibitor or monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285-97
11. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 2007; 68 Suppl. 8: 35-41
12. Pacher P, Kecskemeti V. Trends in the development of new antidepressants: is there a light at the end of the tunnel? Curr Med Chem 2004; 11: 925-43
13. Youdim MBH, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Brit J Pharmacol 2006; 147: S287-96
14. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-70
15. Bruhwyler J, Liégeoist JF, Géczy J. Pirlindole: a selective reversible inhibitor ofmonoamine oxidase A. A review of its preclinical properties. Pharmacol Res 1997; 30: 23-33
16. De Wilde J, Mertens C, Dorpe JV, et al. Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmacol 1997; 12: 41-6
17. Schäpperle O, Eckmann F, Immich H. A double-blind comparison of pirlindole with amitriptyline and imipramine. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 297-302
18. Tanghe A, Geerts S, Van Dorpe J, et al. Double-blind randomised controlled study of the efficacy and tolerability of two reversible monoamine oxidaseAinhibitors, in the treatment of depression. Acta Psychiatrica Scandinavica 1997; 96: 134-41
19. Silverstone T. Introduction to a new generation of antidepressant drugs: pirlindole. Psicopatologia 1987; 7: 432-6
20. Lehmann E, Kinzler E, Stuckmann A, et al. A double-blind comparative study on the use of 225 mg pirlindole and 150 mg desipramine in the treatment of depressive inpatients. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 321-7
21. Renfordt E. A comparison of pirlindole and amitriptyline in a double-blind controlled study. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 311-7
22. Blaha L. A double-blind comparative study of pirlindole and amitriptyline in thirty depressive patients. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 303-9
23. Saletu B, Grü nberger J, Rajna P, et al. Examining pharmaco EEG-based predictions about the antidepressant action of pirlindole by double blind clinical trials. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 291-6
24. Pö ldinger W. Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 3: 283-9
25. De Wilde JE, Geerts S, Van Dorpe J, et al. A double-blind randomised placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psychiatrica Scandinavica 1996; 94: 404-10
26. Geerts S, Vandekerckhove K, Bruhwyler J, et al. Pirlindole versus fluoxetine in the treatment of major depression: a controlled double-blind medium-term study. Prior Velho: Grupo Tecnimede, 2000. (Data on file)
27. Zapletá lek M, Libiger J, Kaspá rkova I, et al. Pyrazidol in the treatment of endogenous depression: a controlled study. Activ Nerv Sup 1981; 23: 200-2
28. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
29. Diversity and heterogeneity [online]. Available from URL: http://www.cochrane-net.org/openlearning/HTML/mod13-4.htm [Accessed 2003 Nov 18]